Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.63 |
| ▸ | CA2 | P00918 | 3/20 | 0.63 |
| ▸ | CA12 | O43570 | 2/20 | 0.63 |
| ▸ | CA7 | P43166 | 2/20 | 0.63 |
| ▸ | CA9 | Q16790 | 2/20 | 0.63 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.63 |
| ▸ | ESR1 | P03372 | 1/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL195116 | 0.87 | CA1 (0.61) | CA1CA2CA12CA7CA9 | |
| SCHEMBL9182180 | 0.86 | RAB9A (0.72) | LMNANPC1MAPTRAB9AMEN1 | |
| SCHEMBL87450 | 0.85 | CA1 (0.83) | CA1CA2CA12CA7CA9 | |
| SCHEMBL9184957 | 0.85 | RAB9A (0.49) | CA1CA2CA12CA7CA9 | |
| SCHEMBL498957 | 0.84 | CA1 (0.58) | CA1CA2CA12CA7CA9 | |
| SCHEMBL29504635 | 0.83 | CA1 (0.79) | CA1CA2CA12CA7CA9 | |
| SCHEMBL21440358 | 0.83 | CA1 (0.79) | CA1CA2CA12CA7CA9 | |
| SCHEMBL30271267 | 0.83 | CA1 (0.79) | CA1CA2CA12CA7CA9 | |
| SCHEMBL7746905 | 0.83 | CA1 (0.79) | CA1CA2CA12CA7CA9 | |
| SCHEMBL27647420 | 0.83 | CA1 (0.79) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160362392-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-9452999-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2016-09-27 | — | — | US | disclosed |
| EP-2673260-B1 | GLUCAGON RECEPTOR MODULATOR | PFIZER (US) | 2016-08-17 | — | — | EP | disclosed |
| US-9382197-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382197-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| CN-103370306-B | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-12-02 | — | — | CN | disclosed |
| US-20150266859-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-9073871-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2015-07-07 | — | — | US | disclosed |
| CN-104744370-A | Glucagon receptor modulators | PFIZER | 2015-07-01 | — | — | CN | disclosed |
| US-20140371467-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2014-12-18 | — | — | US | disclosed |
| EP-2170065-A1 | DIPHENYL SUBSTITUTED ALKANES | Merck Sharp & Dohme Corp. (US) | 2010-04-07 | — | — | EP | disclosed |
| EP-1814877-B1 | DIPHENYL SUBSTITUTED ALKANES AS FLAP INHIBITORS | MERCK & CO INC (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2008156721-A1 | DIPHENYL SUBSTITUTED ALKANES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20070287736-A1 | Diphenyl Substituted Alkanes as Flap Inhibitors | MERCK SHARP & DOHME CORP. | 2007-12-13 | — | — | US | disclosed |
| US-20070287736-A1 | Diphenyl Substituted Alkanes as Flap Inhibitors | MERCK SHARP & DOHME CORP. | 2007-12-13 | — | — | US | disclosed |
| US-20070287736-A1 | Diphenyl Substituted Alkanes as Flap Inhibitors | MERCK SHARP & DOHME CORP. | 2007-12-13 | — | — | US | disclosed |
| EP-1814877-A2 | DIPHENYL SUBSTITUTED ALKANES AS FLAP INHIBITORS | Merck & Co., Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006044602-A2 | DIPHENYL SUBSTITUTED ALKANES AS FLAP INHIIBITORS | MERCK & CO., INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-4015010-A | ANTIOBESITY, ANTIDIABETIC, HYPOLIPIDEMIC AGENTS | SANDOZ, INC. (US) | 1977-03-29 | — | — | US | disclosed |
| US-4015010-A | ANTIOBESITY, ANTIDIABETIC, HYPOLIPIDEMIC AGENTS | SANDOZ, INC. (US) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266859-A1 | GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | CA1 3307/4885CA2 1259/4885CA12 2808/4885 |
| US-20070287736-A1 | Diphenyl Substituted Alkanes as Flap Inhibitors | ALOX5, ALOX15, ALOX15B | CA1 3928/4885CA2 3264/4885CA12 4744/4885 |
| US-20140371467-A1 | GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | CA1 3307/4885CA2 1259/4885CA12 2808/4885 |
| US-20160362392-A1 | GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | CA1 3307/4885CA2 1259/4885CA12 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.